Drug intelligence / Profile preview

OriC628

Development stage: Preclinical
Lead developer: OriCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

OriC628 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy being developed by Shanghai Oricell Therapeutics for the treatment of gastrointestinal malignancies. It is engineered to target Cadherin-17 (CDH17), a calcium-dependent cell-cell adhesion glycoprotein that is highly expressed in colorectal cancer (CRC) and other gastrointestinal tumors but has limited expression in normal tissues. By expressing a CAR specific to CDH17, the patient's T cells are directed to recognize and eliminate CDH17-positive tumor cells. The program is currently in the preclinical/discovery stage of development.

Targets

CDH17 (Cadherin-17)

Beyond the preview

Go deeper on OriC628.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OriC628.

Explore the full profile